Urogen Pharma Stock Market Value
| URGN Stock | USD 12.88 0.18 1.42% |
| Symbol | UroGen |
UroGen Pharma Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share 2.389 | Quarterly Revenue Growth 0.209 | Return On Assets (0.21) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
UroGen Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to UroGen Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of UroGen Pharma.
| 06/05/2024 |
| 12/02/2024 |
If you would invest 0.00 in UroGen Pharma on June 5, 2024 and sell it all today you would earn a total of 0.00 from holding UroGen Pharma or generate 0.0% return on investment in UroGen Pharma over 180 days. UroGen Pharma is related to or competes with Eliem Therapeutics, Inhibrx, Celcuity LLC, Enliven Therapeutics, Ikena Oncology, Xilio Development, and Protara Therapeutics. UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specia... More
UroGen Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure UroGen Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess UroGen Pharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 15.03 | |||
| Value At Risk | (5.50) | |||
| Potential Upside | 5.56 |
UroGen Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for UroGen Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as UroGen Pharma's standard deviation. In reality, there are many statistical measures that can use UroGen Pharma historical prices to predict the future UroGen Pharma's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.61) | |||
| Treynor Ratio | (0.09) |
UroGen Pharma Backtested Returns
UroGen Pharma owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0199, which indicates the firm had a -0.0199% return per unit of risk over the last 3 months. UroGen Pharma exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate UroGen Pharma's Variance of 8.61, risk adjusted performance of (0.02), and Coefficient Of Variation of (2,583) to confirm the risk estimate we provide. The entity has a beta of 1.41, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, UroGen Pharma will likely underperform. At this point, UroGen Pharma has a negative expected return of -0.0589%. Please make sure to validate UroGen Pharma's total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if UroGen Pharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.11 |
Insignificant predictability
UroGen Pharma has insignificant predictability. Overlapping area represents the amount of predictability between UroGen Pharma time series from 5th of June 2024 to 3rd of September 2024 and 3rd of September 2024 to 2nd of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of UroGen Pharma price movement. The serial correlation of 0.11 indicates that less than 11.0% of current UroGen Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.11 | |
| Spearman Rank Test | 0.36 | |
| Residual Average | 0.0 | |
| Price Variance | 0.42 |
UroGen Pharma lagged returns against current returns
Autocorrelation, which is UroGen Pharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting UroGen Pharma's stock expected returns. We can calculate the autocorrelation of UroGen Pharma returns to help us make a trade decision. For example, suppose you find that UroGen Pharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
UroGen Pharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If UroGen Pharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if UroGen Pharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in UroGen Pharma stock over time.
Current vs Lagged Prices |
| Timeline |
UroGen Pharma Lagged Returns
When evaluating UroGen Pharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of UroGen Pharma stock have on its future price. UroGen Pharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, UroGen Pharma autocorrelation shows the relationship between UroGen Pharma stock current value and its past values and can show if there is a momentum factor associated with investing in UroGen Pharma.
Regressed Prices |
| Timeline |
Pair Trading with UroGen Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if UroGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with UroGen Stock
Moving against UroGen Stock
| 0.61 | DRUG | Bright Minds Biosciences Trending | PairCorr |
| 0.57 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.56 | VERA | Vera Therapeutics | PairCorr |
| 0.51 | VCYT | Veracyte | PairCorr |
The ability to find closely correlated positions to UroGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace UroGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back UroGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling UroGen Pharma to buy it.
The correlation of UroGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as UroGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if UroGen Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for UroGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out UroGen Pharma Correlation, UroGen Pharma Volatility and UroGen Pharma Alpha and Beta module to complement your research on UroGen Pharma. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
UroGen Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.